Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Mar 28, 2019 · 10-K · 87 days after period end · 0001493152-19-004137
derived · Computed from the longer spans the company filed.
| Metric | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 | Q4 2015dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | — |
| Net Income | -$609.35K | -$633.86K | -$234.34K | -$362.77K |
| EPS Diluted | — | -$0.02 | -$0.01 | — |
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2018 · filed Mar 28, 2019 · 87 d after period end
